Multiple Sclerosis Mouse Models – Cuprizone-induced demyelination
mouse model
Test the efficacy of your remyelinating or neuroprotective compound, leveraging the gold standard cuprizone-induced demyelination mouse model of Multiple Sclerosis
Cuprizone-induced demyelination mouse model key characteristics
Cuprizone-induced demyelination mouse model is a gold standard mouse model for evaluating efficacy of novel therapeutics for multiple sclerosis focusing primarily oligodendrocyte precursor cells. Wild-type C57BL/6J mice fed a cuprizone-supplemented diet develop progressive demyelination of the corpus callosum and associated white and grey matter structures through selective oligodendrocyte apoptosis driven by copper chelation. Critically, since oligodendrocyte precursor cells are resistant to cuprizone toxicity, remyelination commences following cuprizone withdrawal, creating a defined, controllable window for evaluating remyelination-promoting therapies.
InnoSer performs preclinical efficacy studies in both acute (6-week) and chronic (12-week) cuprizone paradigms, each addressing distinct aspects of demyelination pathophysiology in diseases such as Multiple sclerosis and suited to different therapeutic hypotheses and dosing requirements. Importantly, the acute demyelination and remyelination model (6-week cuprizone diet followed by normal diet) captures oligodendrocyte loss, corpus callosum demyelination, and subsequent spontaneous OPC-driven remyelination within a relatively short disease and efficacy dosing window, enabling you to obtain quick insights into your compound’s efficacy. On the other hand, the chronic demyelination model (12-week cuprizone diet) enables longer dosing paradigms.
✓ InnoSer offers preclinical efficacy studies using the acute (6-week) and chronic (12-week) cuprizone paradigms
✓ Clemastine is available as positive control to benchmark the efficacy of your novel compounds
✓ Visually evoked potentials (VEP) available as a translationally relevant functional readout
✓ Histopathology (e.g., MBP, Caspr) used as endpoint structural readout to quantify degree of remyelination and paranodal junction integrity in the corpus callosum
As a preclinical immunology CRO, InnoSer offers well-established and clinically relevant multiple sclerosis mouse models, complemented with standardized study protocols to ensure consistency and reproducibility of your results. In addition, InnoSer offers preclinical research services using the lysolecithin-induced mouse model of multiple sclerosis and EAE mouse model. While both cuprizone-induced mouse model and lyolecithin mouse models enable you to test efficacy of compounds directed at remylienaiton, the EAE mouse model allows you to focus on the inflammatory component of Multiple sclerosis. However, as all models have their unique characteristics, we recommend discussing your study setup in close collaboration with our experts.
Align your dosing strategy with the biology
The cuprizone model offers flexible study designs spanning disease prevention, symptomatic intervention, and remyelination therapies. Depending on your therapeutic mechanism and development objectives, compound administration can be initiated at different stages of pathology progression.
InnoSer’s neuroscience team will help you match your compound’s mechanism to the right intervention window, model design, and endpoint panel — so your first in vivo study generates data that actually informs your next decision.
| Study type | Recommended dosing window | Typical applications |
|---|---|---|
| Preventive studies | Before cuprizone exposure or during the first week of cuprizone feeding. | Evaluate compounds targeting oligodendrocyte stress, apoptosis, metabolic dysfunction, or early neuroinflammatory processes before extensive demyelination develops. |
| Symptomatic studies | Weeks 2–6 of cuprizone exposure. | Assess therapeutic efficacy after pathology is established, including effects on neuroinflammation, demyelination, axonal damage, and disease progression. |
| Remyelination studies | Following cuprizone withdrawal (acute model) or during recovery from chronic cuprizone exposure. | Evaluate compounds that promote oligodendrocyte regeneration, remyelination, and functional recovery following established demyelinating lesions. |
Cuprizone-induced mouse model validation datasets
La démyélinisation fonctionnelle a été évaluée à l'issue de la période d'exposition à la cuprizone de 6 semaines à l'aide d'enregistrements de potentiels évoqués visuels (PEV), en analysant à la fois la latence (conduction des potentiels d'action) et l'amplitude (indiquant une lésion axonale ou une démyélinisation persistante).
(A) VEP latency was significantly prolonged in cuprizone-treated mice compared with untreated controls, indicating impaired signal conduction through the visual pathway as a consequence of demyelination (**p < 0.0001 vs. baseline; Two-way ANOVA with Dunnett’s multiple comparisons test; N = 10).
(B) L'amplitude du VEP était plus élevée à la semaine 6 par rapport à la valeur initiale, mais restait identique chez les animaux traités à la cuprizone et chez les animaux témoins, ce qui indique l'absence de perte axonale (ANOVA à deux facteurs avec test de comparaisons multiples de Dunnett ; N = 10). Les données sont présentées sous forme de moyenne ± écart-type.
Functional demyelination was assessed at the end of the 12-week cuprizone exposure period using visual evoked potentials (VEPs), evaluating both latency (conduction of action potentials) and amplitude (axonal integrity).
(A) VEP latency was significantly prolonged in cuprizone-treated mice compared with untreated controls, indicating impaired signal conduction through the visual pathway (****p < 0.0001 vs. baseline; Two-way ANOVA with Dunnett’s multiple comparisons test; N = 5-32).
(B) VEP amplitude remained comparable between cuprizone-treated and control animals, demonstrating no axonal loss (Two-way ANOVA with Dunnett’s multiple comparisons test; N = 6-8). Data are represented as mean ± SD.
Key readouts in the Cuprizone mouse model:
Les personnes qui travaillent sur vos recherches
Sofie Carmans, docteure
Chercheur principal en neurologie
Dirige une équipe d'experts scientifiques possédant une vaste expérience de nos modèles de neurologie afin de vous aider à choisir le modèle le plus adapté et vous guide dans votre conception optimale conception d’étude. Nous vous proposons la solution pour accélérerele rythme le développement de vos médicaments.
Université de Hasselt/BIOMED
Dans le cadre d'une initiative conjointe visant à faire progresser la recherche préclinique sur la sclérose en plaques, InnoSer collabore avec des chercheurs de BIOMED, qui se concentrent sur les mécanismes immunologiques, la myélinisation et les processus de lésions cérébrales dans la SEP.
Foire aux questions
What reference compounds can InnoSer work with in the cuprizone mouse model?
For preclinical efficacy studies in the cuprizone mouse model, InnoSer recommends selecting Clemastine as the reference benchmark for your new compound. Clemastine fumarate is a well-established, approved antihistamine drug. Its mechanism of action is antagonism of the M1 muscarinic acetylcholine receptor (M1R) on oligodendrocyte precursor cells (OPCs), which removes a negative regulatory signal for OPC differentiation into mature myelinating oligodendrocytes.
Furthermore, across the scientific literature, Clemastine fumarate has a well-characterised dose-response relationship in the cuprizone model, enhancing remyelination (Li et al., 2015), and has been tested in clinical trials in Multiple Sclerosis patients (Green et al., 2017). This provides you with a direct, translational benchmark that helps link your efficacy datasets to the published clinical literature.
How does the cuprizone mouse model differ from EAE mouse model of multiple sclerosis that InnoSer works with?
The key distinction between the cuprizone-induced mouse model and the EAE mouse model lies in the immune mechanism driving demyelination.
The cuprizone model induces oligodendrocyte apoptosis through metabolic toxicity, with demyelination occurring in the absence of significant peripheral adaptive immune infiltration, in contrast to the EAE model, T and B lymphocytes do not play a central role in the development of demyelinating pathology. Therefore, the cuprizone-induced mouse model is more suitable for compounds targeting oligodendrocyte biology, oligodendrocyte precursor cell (OPC) differentiation and repair pathways, without the confounding influence of immune‑mediated processes.
In the EAE mouse model, by contrast, the disease pathology of multiple sclerosis, is driven by T and B cell-mediated neuroinflammation. Therefore, for compounds primarily targeting peripheral T cell or B cell-mediated immunity, the EAE model is more appropriate.
Contact our team to discuss which model best fits your compound’s mechanism of action.
What is the value of adding VEP as a readout in my preclinical efficacy study in the cuprizone model?
Visually evoked potentials (VEPs) measure the brain’s electrical response to visual stimuli, providing a direct functional assessment of myelin integrity along the visual pathway. In clinical practice, this method is used to assess the functional integrity of the visual pathways, particularly in the context of demyelinating disease, such as Multiple sclerosis.
In preclinical mouse models, functional assessment using VEPs offers a sensitive and translational measure of myelin integrity; demyelination slows the conduction of action potentials, which is reflected as a prolongation of VEP latency, while a reduction in amplitude may indicate axonal injury or persistent demyelination (Leocani et al., 2018). In accordance, subsequent remyelination restores the signal conduction velocity.
VEPs therefore serve as a functional biomarker of myelin repair and complement structural readouts such as myelin basic protein (MBP) or the paranode marker Contactin-Associated Protein (Caspr) quantification and histological analysis (Caverzasi et al., 2023; Green et al., 2017). Together, the cuprizone model and VEP readout constitute a powerful experimental framework for evaluating the remyelinating efficacy of pharmacological agents.
Discover Other Relevant Mouse Models
Découvrez les dernières recherches d'InnoSer
![Neurosciences translationnelles : profilage longitudinal complet des souris femelles et mâles porteurs de la mutation Tau[P301S]](https://www.innoserlaboratories.com/wp-content/uploads/2026/06/Female-TauP301S-mice-show-early-spontaneous-hyperactivity-in-automated-home-cages-PhenoTyperTM-229375_1080x323.png)
Neurosciences translationnelles : profilage longitudinal complet des souris femelles et mâles porteurs de la mutation Tau[P301S]
Dans la lettre d'information de ce mois-ci, nous mettons en avant et approfondissons nos connaissances acquises grâce à l'utilisation du modèle murin Tau[P301S] (décrit à l'origine par Allen et al., 2002), ainsi que son applicabilité dans la recherche préclinique. Les femelles et les mâles...
Panels de biomarqueurs cliniquement pertinents pour des études d'efficacité exhaustives sur des modèles murins de la maladie d'Alzheimer
Les modèles murins validés d'InnoSer pour la maladie d'Alzheimer (MA) intègrent des panels de biomarqueurs pertinents sur le plan translationnel — couvrant les espèces de bêta-amyloïde (Aβ), les isoformes phosphorylées de la protéine Tau, ainsi que le marqueur précoce et sensible de la neurodégénérescence que constituent les neurofilaments légers...
![Modèle murin Tau[P301S] dont la sensibilité au composé a été démontrée, destiné à la validation préclinique du concept](https://www.innoserlaboratories.com/wp-content/uploads/2026/03/Proven-Compound-susceptible-TauP301S-mouse-model-for-preclinical-proof-of-concept--1080x675.png)
Modèle murin Tau[P301S] dont la sensibilité au composé a été démontrée, destiné à la validation préclinique du concept
La souris Tau[P301S] reste l'un des modèles in vivo les plus reconnus pour l'évaluation de traitements ciblant les tauopathies, notamment la maladie d'Alzheimer et la démence frontotemporale (DFT). Présentée lors du congrès AD/PD 2025 à Vienne, cette affiche offre un aperçu complet...
Le comportement dans la cage d'origine permet de distinguer les modèles de neurodégénérescence des souris vieillissant normalement
Distinguer la neurodégénérescence pathologique du vieillissement biologique normal constitue un enjeu fondamental en neurosciences précliniques. Présentée lors du congrès AD/PD 2023 à Göteborg, cette affiche — élaborée en collaboration avec Sylics et l’Université libre d’Amsterdam (VU) — établit une...
Accréditation AAALAC
InnoSer a obtenu l'accréditation AAALAC, ce qui témoigne de notre engagement en faveur d'une prise en charge et d'une utilisation responsables des animaux. AAALAC International est une organisation à but non lucratif qui promeut le traitement sans cruauté des animaux dans le domaine scientifique par le biais de programmes volontaires d'accréditation et d'évaluation. Les sites d'InnoSer aux Pays-Bas et en Belgique sont accrédités par l'AAALAC depuis 2016 et 2020, respectivement. Pour en savoir plus sur le programme d'accréditation de l'AAALAC, cliquez ici.
Bien-être animal
Les « 3R » ont une incidence sur tous les domaines, depuis les changements politiques et réglementaires jusqu’au développement et à l’adoption de nouvelles technologies et approches. C’est pourquoi InnoSer s’engage en permanence à suivre ces processus. Les mesures que nous mettons en œuvre optimisent notre capacité à remplacer, réduire et perfectionner l’utilisation des animaux et facilitent notre engagement envers ces principes dans le cadre de la recherche et du développement de médicaments.
info@innoserlaboratories.com
Liens rapides